Ibrutinib-d5

• Description :

  Ibrutinib-d5 (PCI-32765-d5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor[1].

• Product Name Alternative :

  PCI-32765-d5

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Btk

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  98.08

• Solubility :

  10 mM in DMSO|DMF : ≥ 30mg/mL|DMSO : ≥ 30mg/mL|Ethanol : ≥ 0.25mg/mL

• Smiles :

  C=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=C([2H])C([2H])=C([2H])C([2H])=C4[2H])C=C3)C5=C(N)N=CN=C52)CCC1)=O

• Molecular Formula :

  C25H19D5N6O2

• Molecular Weight :

  445.53

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107 (29) :13075-80.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1553977-17-5]